Latest Institutional Placement News

Beetaloo Energy has wrapped up its $5 million Share Purchase Plan with strong shareholder uptake, pending final approval at the upcoming AGM for new share issuance.

Sandon Capital is seeking noteholder approval to amend its 4.8% unsecured notes, offering an 8.5% fixed interest extension and monthly payments, alongside a $10 million conditional note placement.

Arafura Rare Earths has secured A$350 million through a two-tranche placement, backed by major shareholder Hancock Prospecting, to fund the construction of its Nolans Rare Earths Project.

Electro Optic Systems (ASX:EOS) invites eligible shareholders to participate in a capped A$25 million Share Purchase Plan at the same price as its recent A$150 million institutional placement, supporting its MARSS acquisition and growth strategy.

Arafura Rare Earths launches a two-tranche A$350 million placement and a A$25 million share purchase plan, closing the equity funding gap for its Nolans Rare Earths Project ahead of construction.

Asara Resources continues to unlock substantial high-grade extensions at its Kada Gold Project in Guinea, with recent drilling confirming broad, consistent gold mineralisation beyond existing resources.

Electro Optic Systems (ASX:EOS) has raised A$190 million through institutional and strategic placements at an 9.3% discount, alongside a planned A$25 million share purchase plan, to fund its MARSS acquisition and expand defence capabilities.

GenusPlus is set to transform its business with a $400 million acquisition of MPC Kinetic, diversifying into gas and water sectors and boosting earnings per share by nearly 60%. The deal is backed by a $200 million placement and expanded debt facilities.

Electro Optic Systems (ASX:EOS) has launched a A$175 million capital raising to complete its MARSS acquisition and accelerate expansion in counter-drone and defence technologies, buoyed by a surge in Middle East orders.

Peninsula Energy has completed a fully underwritten A$36.1 million equity raise backed by institutional investors including Washington H. Soul Pattinson, alongside a US$30 million convertible note facility to support its Lance Uranium Project ramp-up.

Syntara Limited offers existing shareholders a discounted share purchase plan to raise about $2 million, following a recent $8 million institutional placement to fund clinical trials and licensing.

Pacific Edge launches a NZ$6 million retail share offer at NZ$0.17 per share following a NZ$25.4 million institutional placement, aiming to strengthen its balance sheet and support Medicare reimbursement efforts for its bladder cancer diagnostics.